Study of Cytokine profile in a Tunisian Parkinson’s Disease cohort
Objective: We aim to study the relationship between clinical features in patients with Parkinson’s disease (PD) and their IL-6 and IL-1β serum levels. Background: According…Cytokine Profiles as Biomarkers for Neurodegenerative Diseases: An inflammatory study on Parkinson’s Disease and Tauopathies
Objective: To investigate the diagnostic and prognostic value of cytokine profiles in cerebrospinal fluid (CSF) and serum of patients with Parkinson's Disease (PD), Progressive Supranuclear…Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease
Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?
Objective: Valosin-containing protein (VCP) mutation causes a multiorgan disease characterized by inclusion body myopathy, Paget disease and frontotemporal dementia, more rarely by Charcot-Marie-Tooth disease type…Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease
Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.
Objective: To investigate the effect of the structurally targeted allosteric regulator GT-02287 on rotenone-induced neurotoxic effects in a Parkinson’s disease animal model. Background: Mutations in…Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease
Objective: To explore the association between Parkinson’s disease (PD) motor symptoms and CSF biomarkers for neuroinflammation and neurodegeneration. Background: Previous in vivo and post mortem…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 25
- Next Page »